Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab with or without Tiragolumab in untreated advanced hepatocellular carcinoma
2023-503422-39-00Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Tecentriq + Avastin with Tecentriq + Avastin + tiragolumab (2 arms). Primary endpoints: Investigator-assessed progression-free survival and Overall survival. Started Oct 2023; status: completed.
02
Drugs
atezolizumabbevacizumabtiragolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-503422-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503422-39-00.